OR WAIT null SECS
December 18, 2015.
The treatment market for pancreatic cancer is set to grow from its current level of $1.9 billion to $2.9 billion by 2021, driven primarily by an increased prevalence of the disease, according to GBI Research.
The company’s latest report states that the will come despite developments in diagnostics and a pipeline of promising new drugs.
Adam Bradbury, GBI Research analyst, says that there are six pancreatic cancer drugs expected to gain approval within the forecast period, all of which have demonstrated significant improvement in progression-free survival and/or overall survival in clinical trials.
Bradbury explains: “The six drugs expected to gain approval within the forecast period are Threshold’s TH-302, Merrimack’s Onivyde (in Europe), NewLink Genetic’s HyperAcute Pancreas, Cancer Advances’ G17DT, Immunomedics’ Clivatuzumab Tetraxetan, and Incyte’s Ruxolitinib Phosphate.
“However, these drugs are not expected to significantly impact the market because of their high cost-to-benefit ratio, which will severely limit their sales by 2021.” Bardbury adds that most of the drugs likely to be approved during the forecast period will be administered as combination therapies, "which will prevent companies charging premium prices and limit their market share.”